Theo Z. Hirsch

Paris, 75006, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Journal: medRxiv : the preprint server for health sciences
Published: December 03, 2025

Global Re-Analysis Confirms Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma. Comment on Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83.

Global Re-Analysis Confirms Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma. Comment on Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83.

Journal: Cancers
Published: November 12, 2025

Hepatoblastoma for pathologists in 2025

Hepatoblastoma for pathologists in 2025

Journal: Annales de pathologie
Published: October 30, 2025

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Journal: Journal of hepatology
Published: October 15, 2025

Intratumour ploidy heterogeneity and clonal evolution in hepatocellular carcinoma.

Intratumour ploidy heterogeneity and clonal evolution in hepatocellular carcinoma.

Journal: Journal of hepatology
Published: May 12, 2025

Molecular evolution of mosaic chromosome 18 copy-number alterations from gametes to hepatoblastoma.

Molecular evolution of mosaic chromosome 18 copy-number alterations from gametes to hepatoblastoma.

Journal: JHEP reports : innovation in hepatology
Published: May 02, 2025

Immune exclusion in hepatoblastoma: Is β-catenin to blame again?

Immune exclusion in hepatoblastoma: Is β-catenin to blame again?

Journal: Journal of hepatology
Published: April 08, 2025

Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypes.

Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypes.

Journal: Nature communications
Published: February 20, 2025

Targeting ATR to overcome cisplatin resistance in hepatoblastoma.

Targeting ATR to overcome cisplatin resistance in hepatoblastoma.

Journal: Journal of hepatology
Published: November 04, 2024

Hepatoblastoma in a patient with neurofibromatosis type 1: A case report.

Hepatoblastoma in a patient with neurofibromatosis type 1: A case report.

Journal: Cancer genetics
Published: October 19, 2024

Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC.

Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC.

Journal: JHEP reports : innovation in hepatology
Published: March 27, 2024

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

Journal: Gut
Published: January 12, 2024
Showing 1-12 of 39

Last Updated: 09/26/2026